People on the Move
Eleven Biotherapeutics
Clinical-stage biopharmaceutical company Eleven Biotherapeutics has appointed ex-Merck and BSM executive Wendy Dixon to its Board of Directors.
Eleven, which develops biologics to treat eye diseases, said it picked Dixon for her experience as former Chief Marketing Officer and President of Global Marketing for Bristol Myers Squibb, and Senior Vice President of Marketing at Merck and Co.
“Wendy’s extensive experience will be invaluable to Eleven as we continue to look to expand, develop and commercialize our ophthalmic pipeline, including our lead product candidate, EBI-005, which is in Phase 3 clinical development for dry eye disease and Phase 2 clinical development for allergic conjunctivitis,” said CEO Abbie Celniker.
Dixon has also worked as a senior advisor to The Monitor Group, now the consultancy Monitor Deloitte, as well as executive management positions at West Pharmaceuticals, Osteotech and Centocor, and marketing and regulatory roles at SmithKline and French (now GSK).
